Company intelligence / Profile preview
Notitia Biotechnologies
Monmouth Junction, New Jersey, United Statesnotitiabio.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
Notitia Biotechnologies has completed early phases of clinical trials for its lead candidate, NBT-NM108, which promotes the Foundation Guild bacteria in the gut microbiome. The company has received FDA approval for a Phase 2a trial in diabetic and prediabetic patients.
- Therapeutic areas
- GastroenterologyNephrologyEndocrinologyOncologyRare DiseasesNeurology
- Modalities
- Live Biotherapeutic Products (LBPs)Prebioticsand Fibers
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Notitia Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Notitia Biotechnologies.